CD88 Antibody (S5/1): sc-53795

CD88 Antibody (S5/1) is a mouse monoclonal IgG2a antibody that detects CD88 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). CD88, also known as the C5a receptor (C5aR), is a G protein-coupled integral membrane protein that plays a crucial role in the immune response by serving as a receptor for the inflammatory peptide C5a. This receptor is predominantly expressed on immune cells such as neutrophils, monocytes, macrophages, and mast cells, as well as on epithelial and endothelial cells, highlighting CD88′s importance in mediating inflammatory processes. The interaction between C5a and CD88 triggers a cascade of signaling events that lead to the production of acute phase proteins in the liver, which are vital for the body′s response to inflammation and infection. Furthermore, elevated levels of CD88 in the brain have been linked to neuroinflammation, suggesting CD88′s involvement in various neurological disorders. Research has also indicated that the C5a/CD88 axis may contribute to the pathogenesis of rheumatoid arthritis and enhance the sensitivity of human bronchial epithelial cells to C5a in the presence of environmental irritants such as cigarette smoke. Anti-CD88 antibody (S5/1) is an essential tool for researchers investigating the complex roles of CD88 in inflammation and immune responses.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD88 Antibody (S5/1) References:

1. Expression of the anaphylatoxin receptor C5aR (CD88) by human articular chondrocytes.  |  Onuma, H., et al. 2002. Rheumatol Int. 22: 52-5. PMID: 12070675
2. Expression of C5aR (CD88) of synoviocytes isolated from patients with rheumatoid arthritis and osteoarthritis.  |  Yuan, G., et al. 2003. Chin Med J (Engl). 116: 1408-12. PMID: 14527377
3. Early expression changes of complement regulatory proteins and C5A receptor (CD88) on leukocytes after multiple injury in humans.  |  Amara, U., et al. 2010. Shock. 33: 568-75. PMID: 19864971
4. PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells.  |  Subramanian, H., et al. 2011. Mol Pharmacol. 79: 1005-13. PMID: 21441599
5. Expressions of C5a and its receptor CD88 after spinal cord injury in C3-deficient mice.  |  Guo, Q., et al. 2013. Scand J Immunol. 77: 224-9. PMID: 23033813
6. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).  |  Nitta, H., et al. 2013. Clin Cancer Res. 19: 2004-13. PMID: 23287562
7. Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma.  |  Staab, EB., et al. 2014. Int Immunopharmacol. 21: 293-300. PMID: 24859057
8. Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies.  |  Elsner, J., et al. 1996. Eur J Immunol. 26: 1560-4. PMID: 8766561
9. Differential regulation of the C3a and C5a receptors (CD88) by IFN-gamma and PMA in U937 cells and related myeloblastic cell lines.  |  Burg, M., et al. 1996. J Immunol. 157: 5574-81. PMID: 8955209
10. The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization.  |  Bock, D., et al. 1997. Eur J Immunol. 27: 1522-9. PMID: 9209506

The preferred CD88 antibody is CD88 Antibody (B-6): sc-271949.